{"id":6773,"date":"2024-10-19T18:55:31","date_gmt":"2024-10-19T18:55:31","guid":{"rendered":"https:\/\/ibsal.es\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\/"},"modified":"2025-03-10T18:09:38","modified_gmt":"2025-03-10T18:09:38","slug":"ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii","status":"publish","type":"post","link":"https:\/\/ibsal.es\/en\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\/","title":{"rendered":"IBSAL obtains again funding from the Instituto de Salud Carlos III"},"content":{"rendered":"\n<p>The University of Salamanca participates in this ambitious project through the research group Experimental Hepatology and Drug Vectorization (HEVEPHARM), directed by Jos\u00e9 Juan Garc\u00eda Mar\u00edn and attached to IBSAL and CIBEREHD, in close collaboration with the General Digestive Surgery Service of the University Hospital of Salamanca, directed by Luis Mu\u00f1oz-Bellv\u00eds, also a member of IBSAL.<\/p>\n\n<div style=\"height:54px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p><br\/><\/p>\n\n<figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"768\" src=\"https:\/\/ibsal.es\/wp-content\/uploads\/2024\/10\/P6130018-1024x768.jpg\" alt=\"\" class=\"wp-image-2493\" srcset=\"https:\/\/ibsal.es\/wp-content\/uploads\/2024\/10\/P6130018-1024x768.jpg 1024w, https:\/\/ibsal.es\/wp-content\/uploads\/2024\/10\/P6130018-300x225.jpg 300w, https:\/\/ibsal.es\/wp-content\/uploads\/2024\/10\/P6130018-768x576.jpg 768w, https:\/\/ibsal.es\/wp-content\/uploads\/2024\/10\/P6130018-1536x1152.jpg 1536w, https:\/\/ibsal.es\/wp-content\/uploads\/2024\/10\/P6130018.jpg 1600w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n<div style=\"height:56px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p><br\/>Under the coordination of the professor of the Department of Physiology and Pharmacology of the USAL and member of HEVEPHARM Roc\u00edo I. Rodr\u00edguez Mac\u00edas, the Salamancan scientists are working on the identification of non-invasive biomarkers for the early diagnosis and prediction of response to pharmacological treatment of cholangiocarcinoma, a liver cancer that is &#8220;rare, but with a very poor prognosis, partly due to the difficulty of detecting it in the early stages of its development, when it can still be treated surgically&#8221;, according to HEVEPHARM.<\/p>\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The University of Salamanca participates in this ambitious project through the research group Experimental Hepatology and Drug Vectorization (HEVEPHARM), directed by Jos\u00e9 Juan Garc\u00eda Mar\u00edn and attached to IBSAL and [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":6169,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_tribe_ticket_capacity":"0","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[238,239],"tags":[242],"class_list":["post-6773","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-news-highlights","tag-cancer-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.12 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>IBSAL obtains again funding from the Instituto de Salud Carlos III | IBSAL<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibsal.es\/en\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IBSAL obtains again funding from the Instituto de Salud Carlos III\" \/>\n<meta property=\"og:description\" content=\"The University of Salamanca participates in this ambitious project through the research group Experimental Hepatology and Drug Vectorization (HEVEPHARM), directed by Jos\u00e9 Juan Garc\u00eda Mar\u00edn and attached to IBSAL and [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibsal.es\/en\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\/\" \/>\n<meta property=\"og:site_name\" content=\"IBSAL\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-19T18:55:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-10T18:09:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ibsal.es\/wp-content\/uploads\/2024\/10\/image.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1029\" \/>\n\t<meta property=\"og:image:height\" content=\"582\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Adri\u00e1n\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Adri\u00e1n\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\\\/\"},\"author\":{\"name\":\"Adri\u00e1n\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#\\\/schema\\\/person\\\/49d3d31c674e67373fe5f86923d11a6d\"},\"headline\":\"IBSAL obtains again funding from the Instituto de Salud Carlos III\",\"datePublished\":\"2024-10-19T18:55:31+00:00\",\"dateModified\":\"2025-03-10T18:09:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\\\/\"},\"wordCount\":158,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ibsal.es\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/image.png\",\"keywords\":[\"Cancer\"],\"articleSection\":[\"News\",\"News highlights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\\\/\",\"url\":\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\\\/\",\"name\":\"IBSAL obtains again funding from the Instituto de Salud Carlos III | IBSAL\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ibsal.es\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/image.png\",\"datePublished\":\"2024-10-19T18:55:31+00:00\",\"dateModified\":\"2025-03-10T18:09:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#\\\/schema\\\/person\\\/49d3d31c674e67373fe5f86923d11a6d\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ibsal.es\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/image.png\",\"contentUrl\":\"https:\\\/\\\/ibsal.es\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/image.png\",\"width\":1029,\"height\":582},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibsal.es\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IBSAL obtains again funding from the Instituto de Salud Carlos III\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/ibsal.es\\\/en\\\/\",\"name\":\"IBSAL\",\"description\":\"Benchmarks in translational research in biomedicine in Castilla y Le\u00f3n\",\"alternateName\":\"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibsal.es\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#\\\/schema\\\/person\\\/49d3d31c674e67373fe5f86923d11a6d\",\"name\":\"Adri\u00e1n\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6e3f24694c9b4b865ec22323f9ff5263406e1bd1d37dfe67ce6d856895c077a5?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6e3f24694c9b4b865ec22323f9ff5263406e1bd1d37dfe67ce6d856895c077a5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6e3f24694c9b4b865ec22323f9ff5263406e1bd1d37dfe67ce6d856895c077a5?s=96&d=mm&r=g\",\"caption\":\"Adri\u00e1n\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"IBSAL obtains again funding from the Instituto de Salud Carlos III | IBSAL","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibsal.es\/en\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\/","og_locale":"en_US","og_type":"article","og_title":"IBSAL obtains again funding from the Instituto de Salud Carlos III","og_description":"The University of Salamanca participates in this ambitious project through the research group Experimental Hepatology and Drug Vectorization (HEVEPHARM), directed by Jos\u00e9 Juan Garc\u00eda Mar\u00edn and attached to IBSAL and [&hellip;]","og_url":"https:\/\/ibsal.es\/en\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\/","og_site_name":"IBSAL","article_published_time":"2024-10-19T18:55:31+00:00","article_modified_time":"2025-03-10T18:09:38+00:00","og_image":[{"width":1029,"height":582,"url":"https:\/\/ibsal.es\/wp-content\/uploads\/2024\/10\/image.png","type":"image\/png"}],"author":"Adri\u00e1n","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Adri\u00e1n","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibsal.es\/en\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\/#article","isPartOf":{"@id":"https:\/\/ibsal.es\/en\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\/"},"author":{"name":"Adri\u00e1n","@id":"https:\/\/ibsal.es\/en\/#\/schema\/person\/49d3d31c674e67373fe5f86923d11a6d"},"headline":"IBSAL obtains again funding from the Instituto de Salud Carlos III","datePublished":"2024-10-19T18:55:31+00:00","dateModified":"2025-03-10T18:09:38+00:00","mainEntityOfPage":{"@id":"https:\/\/ibsal.es\/en\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\/"},"wordCount":158,"commentCount":0,"image":{"@id":"https:\/\/ibsal.es\/en\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\/#primaryimage"},"thumbnailUrl":"https:\/\/ibsal.es\/wp-content\/uploads\/2024\/10\/image.png","keywords":["Cancer"],"articleSection":["News","News highlights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibsal.es\/en\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibsal.es\/en\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\/","url":"https:\/\/ibsal.es\/en\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\/","name":"IBSAL obtains again funding from the Instituto de Salud Carlos III | IBSAL","isPartOf":{"@id":"https:\/\/ibsal.es\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ibsal.es\/en\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\/#primaryimage"},"image":{"@id":"https:\/\/ibsal.es\/en\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\/#primaryimage"},"thumbnailUrl":"https:\/\/ibsal.es\/wp-content\/uploads\/2024\/10\/image.png","datePublished":"2024-10-19T18:55:31+00:00","dateModified":"2025-03-10T18:09:38+00:00","author":{"@id":"https:\/\/ibsal.es\/en\/#\/schema\/person\/49d3d31c674e67373fe5f86923d11a6d"},"breadcrumb":{"@id":"https:\/\/ibsal.es\/en\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibsal.es\/en\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ibsal.es\/en\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\/#primaryimage","url":"https:\/\/ibsal.es\/wp-content\/uploads\/2024\/10\/image.png","contentUrl":"https:\/\/ibsal.es\/wp-content\/uploads\/2024\/10\/image.png","width":1029,"height":582},{"@type":"BreadcrumbList","@id":"https:\/\/ibsal.es\/en\/ibsal-obtains-again-funding-from-the-instituto-de-salud-carlos-iii\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibsal.es\/en\/"},{"@type":"ListItem","position":2,"name":"IBSAL obtains again funding from the Instituto de Salud Carlos III"}]},{"@type":"WebSite","@id":"https:\/\/ibsal.es\/en\/#website","url":"https:\/\/ibsal.es\/en\/","name":"IBSAL","description":"Benchmarks in translational research in biomedicine in Castilla y Le\u00f3n","alternateName":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibsal.es\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ibsal.es\/en\/#\/schema\/person\/49d3d31c674e67373fe5f86923d11a6d","name":"Adri\u00e1n","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/6e3f24694c9b4b865ec22323f9ff5263406e1bd1d37dfe67ce6d856895c077a5?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6e3f24694c9b4b865ec22323f9ff5263406e1bd1d37dfe67ce6d856895c077a5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6e3f24694c9b4b865ec22323f9ff5263406e1bd1d37dfe67ce6d856895c077a5?s=96&d=mm&r=g","caption":"Adri\u00e1n"}}]}},"_links":{"self":[{"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/posts\/6773","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/comments?post=6773"}],"version-history":[{"count":0,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/posts\/6773\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/media\/6169"}],"wp:attachment":[{"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/media?parent=6773"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/categories?post=6773"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/tags?post=6773"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}